Cordycepin inhibits lipopolysaccharide (LPS)-induced Tumor Necrosis Factor (TNF)-α production via activating AMP-Activated Protein Kinase (AMPK) signaling

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12119-12134

  Zhang, Jian Li ^a   Xu, Ying ^b   Shen, Jie ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

AMPK (AMP activated protein kinase); Cordycepin; Kawasaki disease; LPS (lipopolysaccharide); TNF (tumor necrosis factor )

Indexed keywords

CORDYCEPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; DEOXYADENOSINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; MACROPHAGE; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; CULTURE TECHNIQUE; DRUG EFFECTS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DEOXYADENOSINES; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MUCOCUTANEOUS LYMPH NODE SYNDROME; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904166794     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712119     Document Type: Article

References (41)

1. Dajani, A.S.; Taubert, K.A.; Gerber, M.A.; Shulman, S.T.; Ferrieri, P.; Freed, M.; Takahashi, M.; Bierman, F.Z.; Karchmer, A.W.; Wilson, W.; et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87, 1776-1780.
2. Kato, H.; Koike, S.; Yokoyama, T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979, 63, 175-179.
3. Taubert, K.A.; Rowley, A.H.; Shulman, S.T. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr. Infect. Dis. J. 1994, 13, 704-708.
4. Eberhard, B.A.; Andersson, U.; Laxer, R.M.; Rose, V.; Silverman, E.D. Evaluation of the cytokine response in Kawasaki disease. Pediatr. Infect. Dis. J. 1995, 14, 199-203.
5. Lang, B.A.; Silverman, E.D.; Laxer, R.M.; Lau, A.S. Spontaneous tumor necrosis factor production in Kawasaki disease. J. Pediatr. 1989, 115, 939-943.
6. Leung, D.Y.; Geha, R.S.; Newburger, J.W.; Burns, J.C.; Fiers, W.; Lapierre, L.A.; Pober, J.S. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 1986, 164, 1958-1972.
7. Lin, C.Y.; Lin, C.C.; Hwang, B.; Chiang, B.N. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur. J. Pediatr. 1993, 152, 309-312.
8. Pober, J.S. Endothelial activation: Intracellular signaling pathways. Arthritis Res. 2002, 4, S109-S116.
9. Pober, J.S.; Min, W. Endothelial cell dysfunction, injury and death. Handb. Exp. Pharmacol. 2006, 176, 135-156.
10. Varani, J.; Ward, P.A. Mechanisms of endothelial cell injury in acute inflammation. Shock 1994, 2, 311-319.
11. Andreakos, E.T.; Foxwell, B.M.; Brennan, F.M.; Maini, R.N.; Feldmann, M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002, 13, 299-313.
12. Biedermann, B.C. Vascular endothelium: Checkpoint for inflammation and immunity. News Physiol. Sci. 2001, 16, 84-88.
13. Hui-Yuen, J.S.; Duong, T.T.; Yeung, R.S. TNF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J. Immunol. 2006, 176, 6294-6301.
14. Son, M.B.; Gauvreau, K.; Burns, J.C.; Corinaldesi, E.; Tremoulet, A.H.; Watson, V.E.; Baker, A.; Fulton, D.R.; Sundel, R.P.; Newburger, J.W. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J. Pediatr. 2011, 158, 644-649.
15. Burns, J.C.; Mason, W.H.; Hauger, S.B.; Janai, H.; Bastian, J.F.; Wohrley, J.D.; Balfour, I.; Shen, C.A.; Michel, E.D.; Shulman, S.T.; et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 2005, 146, 662-667.
16. Oishi, T.; Fujieda, M.; Shiraishi, T.; Ono, M.; Inoue, K.; Takahashi, A.; Ogura, H.; Wakiguchi, H. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ. J. 2008, 72, 850-852.
17. Shen, J.; Liang, L.; Wang, C. Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: New implication for Kawasaki disease (KD) treatment. Biochem. Biophys. Res. Commun. 2013, 437, 250-255.
18. Shi, P.; Huang, Z.; Tan, X.; Chen, G. Proteomic detection of changes in protein expression induced by cordycepin in human hepatocellular carcinoma BEL-7402 cells. Methods Find. Exp. Clin. Pharmacol. 2008, 30, 347-353.
19. Chang, W.; Lim, S.; Song, H.; Song, B.W.; Kim, H.J.; Cha, M.J.; Sung, J.M.; Kim, T.W.; Hwang, K.C. Cordycepin inhibits vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 2008, 597, 64-69.
20. Ng, T.B.; Wang, H.X. Pharmacological actions of Cordyceps, a prized folk medicine. J. Pharm. Pharmacol. 2005, 57, 1509-1519.
21. Wong, Y.Y.; Moon, A.; Duffin, R.; Barthet-Barateig, A.; Meijer, H.A.; Clemens, M.J.; de Moor, C.H. Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J. Biol. Chem. 2010, 285, 2610-2621.
22. Tuli, H.S.; Sharma, A.K.; Sandhu, S.S.; Kashyap, D. Cordycepin: A bioactive metabolite with therapeutic potential. Life Sci. 2013, 93, 863-869.
23. Zhang, D.W.; Wang, Z.L.; Qi, W.; Lei, W.; Zhao, G.Y. Cordycepin (3'-deoxyadenosine) down-regulates the proinflammatory cytokines in inflammation-induced osteoporosis model. Inflammation 2014, doi: 10.1007/s10753-014-9827-z.
24. Wang, Z.; Wang, X.; Qu, K.; Zhu, P.; Guo, N.; Zhang, R.; Abliz, Z.; Yu, H.; Zhu, H. Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation. Chem. Biol. Drug Des. 2010, 76, 340-344.
25. Thomadaki, H.; Scorilas, A.; Tsiapalis, C.M.; Havredaki, M. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: Implication of polyadenylation in a cell type specific manner. Cancer Chemother. Pharmacol. 2008, 61, 251-265.
26. Wu, W.C.; Hsiao, J.R.; Lian, Y.Y.; Lin, C.Y.; Huang, B.M. The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother. Pharmacol 2007, 60, 103-111.
27. Tang, J.; Feng, Y.; Tsao, S.; Wang, N.; Curtain, R.; Wang, Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J. Ethnopharmacol. 2009, 126, 5-17.
28. Ducommun, S.; Ford, R.J.; Bultot, L.; Deak, M.; Bertrand, L.; Kemp, B.E.; Steinberg, G.R.; Sakamoto, K. Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662. Am. J. Physiol. Endocrinol. Metab. 2014, 30, 688-696.
29. Zheng, Q.Y.; Jin, F.S.; Yao, C.; Zhang, T.; Zhang, G.H.; Ai, X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem. Biophys. Res. Commun. 2012, 419, 741-747.
30. Wu, C.; Guo, Y.; Su, Y.; Zhang, X.; Luan, H.; Zhu, H.; He, H.; Wang, X.; Sun, G.; Sun, X.; et al. Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the gamma1 subunit. J. Cell. Mol. Med. 2014, 18, 293-304.
31. Zhao, Y.; Joshi-Barve, S.; Barve, S.; Chen, L.H. Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation. J. Am. Coll. Nutr. 2004, 23, 71-78.
32. Chandel, N.S.; Trzyna, W.C.; McClintock, D.S.; Schumacker, P.T. Role of oxidants in NF-κB activation and TNF-α gene transcription induced by hypoxia and endotoxin. J. Immunol. 2000, 165, 1013-1021.
33. Yuan, H.; Perry, C.N.; Huang, C.; Iwai-Kanai, E.; Carreira, R.S.; Glembotski, C.C.; Gottlieb, R.A. LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, 470-479.
34. Jeon, S.M.; Chandel, N.S.; Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485, 661-665.
35. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt Method. Methods 2001, 25, 402-408.
36. Girish, M.; Subramaniam, G. Infliximab treatment in refractory Kawasaki syndrome. Indian J. Pediatr. 2008, 75, 521-522.
37. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol. 2012, 13, 251-262.
38. Zhao, X.; Zmijewski, J.W.; Lorne, E.; Liu, G.; Park, Y.J.; Tsuruta, Y.; Abraham, E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295, 497-504.
39. Cacicedo, J.M.; Yagihashi, N.; Keaney, J.F., Jr.; Ruderman, N.B.; Ido, Y. AMPK inhibits fatty acid-induced increases in NF-κB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2004, 324, 1204-1209.
40. Asehnoune, K.; Strassheim, D.; Mitra, S.; Kim, J.Y.; Abraham, E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-κB. J. Immunol. 2004, 172, 2522-2529.
41. Sanlioglu, S.; Williams, C.M.; Samavati, L.; Butler, N.S.; Wang, G.; McCray, P.B., Jr.; Ritchie, T.C.; Hunninghake, G.W.; Zandi, E.; Engelhardt, J.F. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-κB. J. Biol. Chem. 2001, 276, 30188-30198.